Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients

Molecular and Cellular Proteomics

Volumn 11, Issue 11, 2012, Pages 1457-1467

  Chornoguz, Olesya ^a   Gapeev, Alexei ^a   O'Neill, Michael C ^a   Ostrand Rosenbergs, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CELL PROTEIN; HLA DR7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 ASSOCIATED INVARIANT CHAIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHAGY; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL SIZE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RNA INTERFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDES; PHENOTYPE; PROTEIN BINDING; T-LYMPHOCYTES; TISSUE DONORS; TRANSDUCTION, GENETIC;

EID: 84869235164     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.019232     Document Type: Article

References (40)

1. Fang, L., Lonsdorf, A. S., and Hwang, S. T. (2008) Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128, 2596-2605
2. Mellman, I., Coukos, G., and Dranoff, G. (2011) Cancer immunotherapy comes of age. Nature 480, 480-489
3. Neefjes, J., Jongsma, M.L., Paul, P., and Bakke, O. (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823-836
4. Germain, R. N. (2011) Uncovering the role of invariant chain in controlling MHC class II antigen capture. J. Immunol. 187, 1073-1075
5. Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P., and Ostrand- Rosenberg, S. (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U.S.A. 94, 6886-6891 (Pubitemid 27281960)
6. Humphreys, R. E., Hillman, G. G., von Hofe, E., and Xu, M. (2004) Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell. Mol. Immunol. 1, 180-185
7. Baskar, S., Glimcher, L., Nabavi, N., Jones, R.T., and Ostrand-Rosenberg, S. (1995) Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629
8. Bosch, J. J., Thompson, J. A., Srivastava, M. K., Iheagwara, U. K., Murray, T. G., Lotem, M., Ksander, B. R., and Ostrand-Rosenberg, S. (2007) MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67, 4499-4506 (Pubitemid 46815101)
9. Dissanayake, S. K., Thompson, J. A., Bosch, J. J., Clements, V. K., Chen, P. W., Ksander, B. R., and Ostrand-Rosenberg, S. (2004) Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 64, 1867-1874 (Pubitemid 38428713)
10. Srivastava, M. K., Bosch, J. J., Thompson, J. A., Ksander, B. R., Edelman, M. J., and Ostrand-Rosenberg, S. (2008) Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57, 1493-1504
11. Thompson, J. A., Dissanayake, S. K., Ksander, B. R., Knutson, K. L., Disis, M. L., and Ostrand-Rosenberg, S. (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66, 1147-1154 (Pubitemid 43165984)
12. Thompson, J. A., Srivastava, M. K., Bosch, J. J., Clements, V. K., Ksander, B. R., and Ostrand-Rosenberg, S. (2008) The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol. Immunother. 57, 389-398 (Pubitemid 350295383)
13. Chamuleau, M. E., Souwer, Y., Van Ham, S. M., Zevenbergen, A., Westers, T. M., Berkhof, J., Meijer, C. J., van de Loosdrecht, A. A., and Ossenkoppele, G. J. (2004) Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 64, 5546-5550 (Pubitemid 39095546)
14. van Luijn, M. M., Chamuleau, M. E., Thompson, J. A., Ostrand-Rosenberg, S., Westers, T. M., Souwer, Y., Ossenkoppele, G. J., van Ham, S. M., and van de Loosdrecht, A. A. (2010) Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica 95, 485-493
15. van Luijn, M. M., van den Ancker, W., Chamuleau, M. E., Zevenbergen, A., Westers, T. M., Ossenkoppele, G. J., van Ham, S. M., and van de Loosdrecht, A. A. (2011) Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res. 71, 2507-2517
16. Pauley, R. J., Soule, H. D., Tait, L., Miller, F. R., Wolman, S. R., Dawson, P. J., and Heppner, G. H. (1993) The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur. J. Cancer Prev. 2 67-76
17. Depontieu, F. R., Qian, J., Zarling, A. L., McMiller, T. L., Salay, T. M., Norris, A., English, A. M., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Topalian, S. L. (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 106, 12073-12078
18. Deutsch, E. W., Mendoza, L., Shteynberg, D., Farrah, T., Lam, H., Tasman, N., Sun, Z., Nilsson, E., Pratt, B., Prazen, B., Eng, J. K., Martin, D. B., Nesvizhskii, A. I., and Aebersold, R. A guided tour of the Trans-Proteomic Pipeline. Proteomics 10, 1150-1159
19. Borstnik, B., and Hofacker, G. L. (1985) Functional aspects of the neutral patterns in protein evolution, Guiderland: Academic Press
20. Sotiriadou, R., Perez, S. A., Gritzapis, A. D., Sotiropoulou, P. A., Echner, H., Heinzel, S., Mamalaki, A., Pawelec, G., Voelter, W., Baxevanis, C. N., and Papamichail, M. (2001) Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br. J. Cancer 85, 1527-1534 (Pubitemid 34001585)
21. Salazar, L. G., Fikes, J., Southwood, S., Ishioka, G., Knutson, K. L., Gooley, T. A., Schiffman, K., and Disis, M. L. (2003) Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin. Cancer Res. 9, 5559-5565 (Pubitemid 37499475)
22. Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y. C., Huang, L. Q., Laheru, D. A., Goggins, M., Hruban, R. H., and Jaffee, E. M. (2004) Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200, 297-306 (Pubitemid 39031249)
23. Kessler, J. H., Mommaas, B., Mutis, T., Huijbers, I., Vissers, D., Benckhuijsen, W. E., Schreuder, G. M., Offringa, R., Goulmy, E., Melief, C. J., van der Burg, S. H., and Drijfhout, J. W. (2003) Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluo-rescein-labeled synthetic peptides. Human Immunol. 64, 245-255 (Pubitemid 36197353)
24. Steimle, V., Siegrist, C. A., Mottet, A., Lisowska-Grospierre, B., and Mach, B. (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265, 106-109 (Pubitemid 24253184)
25. Lippolis, J. D., White, F. M., Marto, J. A., Luckey, C. J., Bullock, T. N., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2002) Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J. Immunol. 169, 5089-5097 (Pubitemid 35217178)
26. Suri, A., Lovitch, S. B., and Unanue, E. R. (2006) The wide diversity and complexity of peptides bound to class II MHC molecules. Curr. Opin. Immunol. 18, 70-77 (Pubitemid 43049651)
27. Bhasin, M., Singh, H., and Raghava, G. P. (2003) MHCBN: a comprehensive database of MHC binding and non-binding peptides. Bioinformatics. 19, 665-666 (Pubitemid 36417067)
28. Lata, S., Bhasin, M., and Raghava, G. P. (2009) MHCBN 4.0: A database of MHC/TAP binding peptides and T-cell epitopes. BMC Res. Notes 2, 61
29. Arimilli, S., Cardoso, C., Mukku, P., Baichwal, V., and Nag, B. (1995) Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains. J. Biol. Chem. 270, 971-977
30. Justesen, S., Harndahl, M., Lamberth, K., Nielsen, L. L., and Buus, S. (2009) Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res. 5, 2
31. Nilsson, T., Mann, M., Aebersold, R., Yates, J. R., 3rd, Bairoch, A., and Bergeron, J.J. (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 7, 681-685
32. Purcell, A. W., and Gorman, J. J. (2004) Immunoproteomics: Mass spec-trometry- based methods to study the targets of the immune response. Mol. Cell. Proteomics 3, 193-208 (Pubitemid 38714276)
33. Gelder, C., Davenport, M., Barnardo, M., Bourne, T., Lamb, J., Askonas, B., Hill, A., and Welsh, K. (1998) Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. Int. Immunol. 10, 211-222 (Pubitemid 28085371)
34. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S., and Strominger, J. L. (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178, 27-47 (Pubitemid 23173241)
35. Crotzer, V. L., and Blum, J. S. (2009) Autophagy and its role in MHC-mediated antigen presentation. J. Immunol. 182, 3335-3341
36. Berger, A. C., and Roche, P. A. (2009) MHC class II transport at a glance. J. Cell Sci. 122, 1-4
37. Lechler, R., Aichinger, G., and Lightstone, L. (1996) The endogenous pathway of MHC class II antigen presentation. Immunol. Rev. 151, 51-79 (Pubitemid 26275856)
38. Dissanayake, S. K., Tuera, N., and Ostrand-Rosenberg, S. (2005) Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J. Immunol. 174, 1811-1819 (Pubitemid 40223920)
39. Qi, L., Rojas, J. M., and Ostrand-Rosenberg, S. (2000) Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol. 165, 5451-5461
40. Bosch, J. J., Iheagwara, U. K., Reid, S., Srivastava, M. K., Wolf, J., Lotem, M., Ksander, B. R., and Ostrand-Rosenberg, S. (2010) Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol. Immunother. 59, 103-112